NCT03203369View on ClinicalTrials.gov

Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN

PHASE1TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

June 28, 2017

Primary Completion Date

June 27, 2019

Study Completion Date

June 27, 2019

Conditions
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Interventions
BIOLOGICAL

UCART123

Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor given as a single dose following a lymphodepleting regimen.

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

Sponsors

Lead Sponsor

Cellectis S.A.
All Listed Sponsors
lead

Cellectis S.A.

INDUSTRY

NCT03203369 - Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN | Biotech Hunter | Biotech Hunter